{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:39:46Z","timestamp":1793147986361,"version":"4.5.0"},"reference-count":107,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Sarcoidosis is a multisystem granulomatous disease, associated with significant morbidity and impaired quality of life. Treatment is aimed at recovering organ function, reducing symptom burden and improving quality of life. Because of the heterogeneity and variable disease course, a comprehensive, multidisciplinary approach to care is needed. Comprehensive care includes not only pharmacological interventions, but also supportive measures aimed at relieving symptoms and improving quality of life. The purpose of this review is to summarize the most recent knowledge regarding different aspects of care and propose a structured approach to sarcoidosis management.<\/jats:p>","DOI":"10.3390\/jcm9020390","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T01:25:51Z","timestamp":1580693151000},"page":"390","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Comprehensive Care for Patients with Sarcoidosis"],"prefix":"10.3390","volume":"9","author":[{"given":"Catharina C.","family":"Moor","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivienne","family":"Kahlmann","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Culver","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-6962","authenticated-orcid":false,"given":"Marlies S.","family":"Wijsenbeek","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1513\/AnnalsATS.201707-564OT","article-title":"Disease burden and variability in sarcoidosis","volume":"14","author":"Gerke","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Harper, L.J., Gerke, A.K., Wang, X.F., Ribeiro Neto, M.L., Baughman, R.P., Beyer, K., Drent, M., Judson, M.A., Maier, L.A., and Serchuck, L. (2019). Income and other contributors to poor outcomes in us sarcoidosis patients. Am. J. Respir Crit. Care Med.","DOI":"10.1164\/rccm.201906-1250OC"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1378\/chest.125.3.997","article-title":"Health-related quality of life of persons with sarcoidosis","volume":"125","author":"Cox","year":"2004","journal-title":"Chest"},{"key":"ref_6","first-page":"280","article-title":"The indications for the treatment of sarcoidosis: Wells law","volume":"34","author":"Baughman","year":"2017","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Baughman, R.P., Barriuso, R., Beyer, K., Boyd, J., Hochreiter, J., Knoet, C., Martone, F., Quadder, B., Richardson, J., and Spitzer, G. (2018). Sarcoidosis: Patient treatment priorities. ERJ Open Res.","DOI":"10.1183\/23120541.00141-2018"},{"key":"ref_8","first-page":"75","article-title":"Defining organ involvement in sarcoidosis: The access proposed instrument. Access research group. A case control etiologic study of sarcoidosis","volume":"16","author":"Judson","year":"1999","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12016-014-8450-y","article-title":"The clinical features of sarcoidosis: A comprehensive review","volume":"49","author":"Judson","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1753465816686743","article-title":"Optimizing quality of life in patients with idiopathic pulmonary fibrosis","volume":"11","author":"Geelhoed","year":"2017","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","article-title":"Palliative care in interstitial lung disease: Living well","volume":"5","author":"Kreuter","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MCP.0000000000000604","article-title":"Indications for treatment of sarcoidosis","volume":"25","author":"Nunes","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ccm.2015.08.013","article-title":"Consequences of sarcoidosis","volume":"36","author":"Drent","year":"2015","journal-title":"Clin. Chest Med."},{"key":"ref_14","first-page":"19","article-title":"The wasog sarcoidosis organ assessment instrument: An update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_15","first-page":"117","article-title":"Association between physical functions and quality of life in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccm.2015.08.015","article-title":"Treatment of sarcoidosis","volume":"36","author":"Wijsenbeek","year":"2015","journal-title":"Clin. Chest Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00408-019-00206-7","article-title":"The burden of sarcoidosis symptoms from a patient perspective","volume":"197","author":"Voortman","year":"2019","journal-title":"Lung"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00408-019-00234-3","article-title":"Sarcoidosis and work participation: The need to develop a disease-specific core set for assessment of work ability","volume":"197","author":"Hendriks","year":"2019","journal-title":"Lung"},{"key":"ref_19","unstructured":"Waverijn, G., Spreeuwenberg, P., and Heijmans, M. (2017, January 30). Leven met een Longziekte in Nederland: Cijfers en Trends over de zorg- en Leefsituatie van Mensen met een Longziekte 2016. Available online: https:\/\/www.narcis.nl\/publication\/RecordID\/publicat%3A1003084."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.rmed.2018.09.016","article-title":"Work ability before and after sarcoidosis diagnosis in sweden","volume":"144","author":"Arkema","year":"2018","journal-title":"Respir. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000501657","article-title":"Quality of life of couples living with sarcoidosis","volume":"98","author":"Voortman","year":"2019","journal-title":"Respiration"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0954-6111(98)90007-5","article-title":"Evaluation of quality of life in sarcoidosis patients","volume":"92","author":"Wirnsberger","year":"1998","journal-title":"Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ccm.2008.03.003","article-title":"Quality of life and health status in sarcoidosis: A review of the literature","volume":"29","author":"Drent","year":"2008","journal-title":"Clin. Chest Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1378\/chest.130.4.989","article-title":"Fatigue is associated with quality of life in sarcoidosis patients","volume":"130","author":"Michielsen","year":"2006","journal-title":"Chest"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000092670","article-title":"Relationship between symptoms and quality of life in a sarcoidosis population","volume":"74","author":"Michielsen","year":"2007","journal-title":"Respiration"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/5584_2014_18","article-title":"Fatigue in sarcoidosis and exercise tolerance, dyspnea, and quality of life","volume":"833","author":"Jastrzebski","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00408-018-0144-4","article-title":"Needs, perceptions and education in sarcoidosis: A live interactive survey of patients and partners","volume":"196","author":"Moor","year":"2018","journal-title":"Lung"},{"key":"ref_28","unstructured":"WHO (2019, December 17). Measuring Quality of Life. Available online: https:\/\/www.who.int\/healthinfo\/survey\/whoqol-qualityoflife\/en\/."},{"key":"ref_29","unstructured":"FDA (2019, December 17). Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims."},{"key":"ref_30","first-page":"2","article-title":"Patient reported outcome measures (proms) in sarcoidosis","volume":"34","author":"Thunold","year":"2017","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1055\/s-0037-1602589","article-title":"Quality of life in sarcoidosis","volume":"38","author":"Judson","year":"2017","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1164\/rccm.201410-1785OC","article-title":"Validation and important differences for the sarcoidosis assessment tool. A new patient-reported outcome measure","volume":"191","author":"Judson","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1348\/1359107041557048","article-title":"Measuring fatigue in sarcoidosis: The fatigue assessment scale (fas)","volume":"9","author":"Michielsen","year":"2004","journal-title":"Br. J. Health Psychol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1164\/rccm.200211-1343OC","article-title":"The sarcoidosis health questionnaire: A new measure of health-related quality of life","volume":"168","author":"Cox","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/MCP.0000000000000496","article-title":"The fatigue assessment scale: Quality and availability in sarcoidosis and other diseases","volume":"24","author":"Hendriks","year":"2018","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11136-018-2016-z","article-title":"A systematic review of randomised controlled trials evaluating the use of patient-reported outcome measures (proms)","volume":"28","author":"Ishaque","year":"2019","journal-title":"Qual. Life Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(18)30141-4","article-title":"Patient-reported outcomes: An essential component of oncology drug development and regulatory review","volume":"19","author":"Basch","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: The results of a propensity analysis","volume":"109","author":"Judson","year":"2015","journal-title":"Respir. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11136-013-0438-1","article-title":"A conceptual model of health-related quality of life in sarcoidosis","volume":"23","author":"Victorson","year":"2014","journal-title":"Qual. Life Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Pohle, S., Baty, F., and Brutsche, M. (2016). In-hospital disease burden of sarcoidosis in switzerland from 2002 to 2012. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151940"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0000000000000602","article-title":"Patient perspectives in sarcoidosis","volume":"25","author":"Polish","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"j4891","DOI":"10.1136\/bmj.j4891","article-title":"A three-talk model for shared decision making: Multistage consultation process","volume":"359","author":"Elwyn","year":"2017","journal-title":"BMJ"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/ACM.0000000000000603","article-title":"The patient-as-partner approach in health care: A conceptual framework for a necessary transition","volume":"90","author":"Karazivan","year":"2015","journal-title":"Acad. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S415","DOI":"10.1513\/AnnalsATS.201707-563OT","article-title":"Executive summary of the nhlbi workshop report: Leveraging current scientific advancements to understand sarcoidosis variability and improve outcomes","volume":"14","author":"Maier","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MCP.0000000000000597","article-title":"Nonorgan manifestations of sarcoidosis","volume":"25","author":"Tavee","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1183\/13993003.00604-2016","article-title":"European idiopathic pulmonary fibrosis patient charter: A missed opportunity","volume":"48","author":"Bonella","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/1049732316680203","article-title":"Online peer-to-peer communities in the daily lives of people with chronic illness: A qualitative systematic review","volume":"27","author":"Kingod","year":"2017","journal-title":"Qual. Health Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.288.14.1775","article-title":"Improving primary care for patients with chronic illness","volume":"288","author":"Bodenheimer","year":"2002","journal-title":"JAMA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/jan.12902","article-title":"A metasynthesis of factors affecting self-management of chronic illness","volume":"72","author":"Jaser","year":"2016","journal-title":"J. Adv. Nurs."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Moor, C.C., Gur-Demirel, Y., and Wijsenbeek, M.S. (2019). Feasibility of a comprehensive home monitoring program for sarcoidosis. J. Pers. Med.","DOI":"10.3390\/jpm9020023"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1702089","DOI":"10.1183\/13993003.02089-2017","article-title":"Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis","volume":"51","author":"Broos","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000481827","article-title":"Physical activity and fatigue in patients with sarcoidosis","volume":"95","author":"Bahmer","year":"2018","journal-title":"Respiration"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1002\/hsr2.109","article-title":"Daily life physical activity in patients with chronic stage iv sarcoidosis: A multicenter cohort study","volume":"2","author":"Froidure","year":"2019","journal-title":"Health Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/5584_2017_85","article-title":"Physical functioning and symptoms of chronic fatigue in sarcoidosis patients","volume":"1040","author":"Pilzak","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/17476348.2016.1227244","article-title":"Physical activity and training in sarcoidosis: Review and experience-based recommendations","volume":"10","author":"Strookappe","year":"2016","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00408-015-9784-9","article-title":"Benefits of physical training in sarcoidosis","volume":"193","author":"Strookappe","year":"2015","journal-title":"Lung"},{"key":"ref_58","first-page":"53","article-title":"Does physical training reduce fatigue in sarcoidosis?","volume":"32","author":"Marcellis","year":"2015","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/HCR.0000000000000307","article-title":"Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: A randomized controlled trial","volume":"38","author":"Naz","year":"2018","journal-title":"J. Cardiopulm. Rehabil. Prev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4187\/respcare.04312","article-title":"Effects of inspiratory muscle training in subjects with sarcoidosis: A randomized controlled clinical trial","volume":"61","author":"Karadalli","year":"2016","journal-title":"Respir. Care"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000370126","article-title":"Principles of rehabilitation and reactivation: Interstitial lung disease, sarcoidosis and rheumatoid disease with respiratory involvement","volume":"89","author":"Holland","year":"2015","journal-title":"Respiration"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.genhosppsych.2008.04.010","article-title":"Quality of life, anxiety and depression in sarcoidosis","volume":"30","author":"Goracci","year":"2008","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"00085-2017","DOI":"10.1183\/23120541.00085-2017","article-title":"Feasibility, utility and symptom impact of modified mindfulness training in sarcoidosis","volume":"4","author":"Saketkoo","year":"2018","journal-title":"ERJ Open Res."},{"key":"ref_64","unstructured":"(2019, June 20). TIRED trial: A randomized controlled trial of a web-based psychological Intervention to reduce stress and fatigue in patients with sarcoidosis. Available online: https:\/\/www.trialregister.nl\/trial\/7816."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00408-015-9799-2","article-title":"Cough in sarcoidosis","volume":"194","author":"Tully","year":"2016","journal-title":"Lung"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1183\/13993003.01369-2015","article-title":"Predictors of objective cough frequency in pulmonary sarcoidosis","volume":"47","author":"Sinha","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_67","first-page":"198","article-title":"Use of fluticasone in acute symptomatic pulmonary sarcoidosis","volume":"19","author":"Baughman","year":"2002","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1183\/09031936.99.13613519","article-title":"Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: A pilot study","volume":"13","author":"Greenhalgh","year":"1999","journal-title":"Eur. Respir. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2796.1994.tb00798.x","article-title":"No effect of high-dose inhaled steroids in pulmonary sarcoidosis: A double-blind, placebo-controlled study","volume":"236","author":"Milman","year":"1994","journal-title":"J. Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.chest.2018.06.038","article-title":"Treatment of interstitial lung disease associated cough: Chest guideline and expert panel report","volume":"154","author":"Birring","year":"2018","journal-title":"Chest"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.200909-1451OC","article-title":"Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis","volume":"182","author":"Prasse","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1378\/chest.07-2952","article-title":"Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue","volume":"133","author":"Lower","year":"2008","journal-title":"Chest"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpainsymman.2012.02.016","article-title":"Armodafinil for sarcoidosis-associated fatigue: A double-blind, placebo-controlled, crossover trial","volume":"45","author":"Lower","year":"2013","journal-title":"J. Pain Symptom Manag."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000314225","article-title":"Everyday cognitive failure in sarcoidosis: The prevalence and the effect of anti-tnf-alpha treatment","volume":"80","author":"Elfferich","year":"2010","journal-title":"Respiration"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rmed.2010.09.015","article-title":"Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis","volume":"105","author":"Parambil","year":"2011","journal-title":"Respir. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to ivig and anti-tnf alpha treatment","volume":"126","author":"Tavee","year":"2017","journal-title":"Respir. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.rmed.2018.03.021","article-title":"Sleep disturbance and symptom burden in sarcoidosis","volume":"144S","author":"Benn","year":"2018","journal-title":"Respir. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.4187\/respcare.02080","article-title":"Factors associated with fatigue in sarcoidosis","volume":"59","author":"Fleischer","year":"2014","journal-title":"Respir. Care"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2016.05.010","article-title":"Predictors of fatigue in sarcoidosis: The value of exercise testing","volume":"116","author":"Strookappe","year":"2016","journal-title":"Respir. Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"van Manen, M.J.G., Wester, V.L., van Rossum, E.F.C., van den Toorn, L.M., Dorst, K.Y., de Rijke, Y.B., and Wijsenbeek, M.S. (2019). Scalp hair cortisol and testosterone levels in patients with sarcoidosis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215763"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.rmed.2017.11.008","article-title":"Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study","volume":"138S","author":"Hendriks","year":"2018","journal-title":"Respir. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"BIO52","DOI":"10.1167\/iovs.16-21291","article-title":"Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain","volume":"58","author":"Culver","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_83","first-page":"36","article-title":"Perceptions and beliefs in sarcoidosis","volume":"27","author":"Ireland","year":"2010","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/ajrccm.163.2.2004177","article-title":"Depression in sarcoidosis","volume":"163","author":"Chang","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_85","first-page":"59","article-title":"Quality of life and depressive symptoms in patients suffering from sarcoidosis","volume":"15","author":"Drent","year":"1998","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_86","first-page":"115","article-title":"What comorbidities accompany sarcoidosis? A large cohort (n=1779) patients analysis","volume":"32","author":"Boros","year":"2015","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00408-017-0076-4","article-title":"The burden of comorbidity and complexity in sarcoidosis: Impact of associated chronic diseases","volume":"196","author":"Bosch","year":"2018","journal-title":"Lung"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/crj.12398","article-title":"The influence of comorbidities on mortality in sarcoidosis: A observational prospective cohort study","volume":"11","author":"Nowinski","year":"2017","journal-title":"Clin. Respir. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00408-007-9008-z","article-title":"Comorbid illnesses and chest radiographic severity in african-american sarcoidosis patients","volume":"185","author":"Westney","year":"2007","journal-title":"Lung"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/17512433.2018.1486706","article-title":"Treatment of sarcoidosis: Grading the evidence","volume":"11","author":"James","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Paramothayan, N.S., Lasserson, T.J., and Jones, P.W. (2005). Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst. Rev., CD001114.","DOI":"10.1002\/14651858.CD001114.pub2"},{"key":"ref_92","unstructured":"Statement on sarcoidosis (1999). Joint statement of the american thoracic society (ats), the european respiratory society (ers) and the world association of sarcoidosis and other granulomatous disorders (wasog) adopted by the ats board of directors and by the ers executive committee, february 1999. Am. J. Respir. Crit. Care Med., 160, 736\u2013755."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1753466619868935","DOI":"10.1177\/1753466619868935","article-title":"Contemporary optimized practice in the management of pulmonary sarcoidosis","volume":"13","author":"Aryal","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0002-9343(66)90216-6","article-title":"Course of pulmonary sarcoidosis with and without corticosteriod therapy as determined by pulmonary function studies","volume":"41","author":"Sharma","year":"1966","journal-title":"Am. J. Med."},{"key":"ref_95","first-page":"271","article-title":"A ten-year study of corticosteroid treatment of pulmonary sarcoidosis","volume":"134","author":"Johns","year":"1974","journal-title":"Johns Hopkins Med. J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","article-title":"Multinational evidence-based world association of sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: Integrating systematic literature research and expert opinion of sarcoidologists worldwide","volume":"19","author":"Cremers","year":"2013","journal-title":"Curr. Opin Pulm. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"key":"ref_98","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: Results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7326\/0003-4819-111-5-437","article-title":"Effective reduction in the serum 1,25-dihydroxyvitamin d and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy","volume":"111","author":"Adams","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/archderm.1991.01680060108015","article-title":"Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature","volume":"127","author":"Zic","year":"1991","journal-title":"Arch. Dermatol."},{"key":"ref_101","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory fdg pet-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","article-title":"Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab","volume":"115","author":"Crommelin","year":"2016","journal-title":"Respir. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jdcr.2019.02.006","article-title":"Resolution of cutaneous sarcoidosis after janus kinase inhibitor therapy for concomitant polycythemia vera","volume":"5","author":"Wei","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0953-6205(03)00076-1","article-title":"Sarcoidosis: Benefits of a multidisciplinary approach","volume":"14","author":"Drent","year":"2003","journal-title":"Eur. J. Intern. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/2\/390\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:53:43Z","timestamp":1760172823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/2\/390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":107,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["jcm9020390"],"URL":"https:\/\/doi.org\/10.3390\/jcm9020390","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}